Chemical inhibitors of ZSCAN16 can exert their inhibitory effects through various mechanisms, primarily by targeting cellular processes that are fundamental for the protein's function. Alsterpaullone, Dinaciclib, and Flavopiridol operate by inhibiting cyclin-dependent kinases (CDKs), which are essential for cell cycle control and transcriptional regulation, both of which are processes that ZSCAN16 is involved in. For instance, Alsterpaullone disrupts necessary phosphorylation events, while Flavopiridol specifically disrupts CDK9's role in transcription elongation, which could be a critical component of ZSCAN16's activity in gene regulation. Similarly, Dinaciclib's broad inhibition of CDKs would lead to a decrease in ZSCAN16's regulatory capacity by preventing the cell from progressing through the cycle phases where ZSCAN16 is active.
Continuing along the same lines, SNS-032, Palbociclib, Ribociclib, Seliciclib, Milciclib, AZD5438, Roscovitine, and AT7519 also target CDKs but with varying specificities. For example, Palbociclib and Ribociclib selectively inhibit CDK4/6, which are kinases that control the G1-S phase transition, a phase where ZSCAN16 might play a role. Consequently, the inhibition of these kinases can inhibit the functionality of ZSCAN16 by disrupting its phase-specific activities. Seliciclib and Roscovitine, on the other hand, have a broader range of CDK targets, including those directly involved in controlling the transcription machinery, which is integral to the activity of ZSCAN16. Milciclib and AT7519 also contribute to the inhibition by altering the cell cycle and transcriptional activities, affecting ZSCAN16's regulatory functions. In contrast, JQ1 targets BET bromodomain proteins, leading to changes in chromatin states and affecting transcription factors' activities, including that of ZSCAN16, thus indirectly inhibiting its ability to regulate gene expression. These chemical inhibitors work in concert to disrupt the cellular environment and processes necessary for ZSCAN16's function, thereby inhibiting its activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that could inhibit ZSCAN16 by preventing the phosphorylation events necessary for its activity or interaction with other cellular proteins involved in transcription regulation. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is known to inhibit CDKs, which are crucial for cell cycle progression and transcriptional regulation, processes in which ZSCAN16 is involved. Inhibition of these CDKs can lead to reduced activity of ZSCAN16. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDK9, a kinase involved in transcription elongation. By inhibiting CDK9, Flavopiridol can disrupt the transcriptional programs where ZSCAN16 is a necessary factor, thus inhibiting its function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 inhibits BET bromodomain proteins, which can lead to altered chromatin states and affect the activity of transcription factors like ZSCAN16, decreasing its ability to regulate gene expression. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective CDK inhibitor affecting CDK2, CDK7, and CDK9. ZSCAN16 relies on the proper function of CDKs for its role in transcription; thus, inhibition of these kinases can inhibit ZSCAN16 activity. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib selectively inhibits CDK4 and CDK6. Since ZSCAN16 function is dependent on the cell cycle phase that is regulated by these kinases, Palbociclib can inhibit the functionality of ZSCAN16. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib, a CDK4/6 inhibitor, can inhibit ZSCAN16 by disrupting the cell cycle phase specific activities and transcriptional roles that ZSCAN16 might be involved in. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib inhibits various CDKs and could inhibit ZSCAN16 by altering the cell cycle and transcriptional activities that ZSCAN16 is involved in, particularly affecting its regulatory roles. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9. Since ZSCAN16's function can be linked to transcription and cell cycle regulation, inhibition of these kinases can directly inhibit ZSCAN16's activity. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 inhibits multiple CDKs, and thereby can inhibit ZSCAN16 by impacting the cell cycle phases and transcriptional regulation that are important for the functional activity of ZSCAN16. | ||||||